Purpose
Guide health care providers in determining recommended vaccines for each age group.
How to use the schedule
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
Ages 19 Years or Older
Legend
To make vaccination recommendations, healthcare providers should:
| Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity | Recommended vaccination for adults with an additional risk factor or another indication | Recommended vaccination based on shared clinical decision-making | No Guidance/Not Applicable |
| Vaccine | 19-26 years | 27-49 years | 50-64 years | ≥65 years | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COVID-19  |
1 or more doses of 2024–2025 vaccine (See Notes) | 2 or more doses of 2024-2025 vaccine (See Notes) |
||||||||||||
| Influenza inactivated (IIV3, ccIIV3) Influenza recombinant (RIV3) |
1 dose annually | 1 dose annually (HD–IIV3, RIV3, or aIIV3 preferred) |
||||||||||||
| Influenza inactivated (aIIV3; HD–IIV3) Influenza recombinant (RIV3) |
Solid organ transplant (See Notes) | |||||||||||||
| Influenza live, attenuated (LAIV3) |
1 dose annually | |||||||||||||
| Respiratory Syncytial Virus (RSV) |
Seasonal administration during pregnancy.
(See Notes) |
|
≥75 years | |||||||||||
| Tetanus, diphtheria, pertussis (Tdap or Td) |
1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes) | |||||||||||||
| 1 dose Tdap, then Td or Tdap booster every 10 years | ||||||||||||||
| Measles, mumps, rubella (MMR) |
1 or 2 doses depending on indication (if born in 1957 or later) |
|
||||||||||||
| Varicella (VAR) |
|
2 doses | ||||||||||||
| Zoster recombinant (RZV) |
2 doses for immunocompromising conditions (See Notes) |
2 doses | ||||||||||||
| Human papillomavirus (HPV) |
2 or 3 doses depending on age at initial vaccination or condition | 27 through 45 years | ||||||||||||
| Pneumococcal (PCV15, PCV20,PCV21, PPSV23) |
See Notes | |||||||||||||
| See Notes | ||||||||||||||
| Hepatitis A (HepA) |
2, 3, or 4 doses depending on vaccine | |||||||||||||
| Hepatitis B (HepB) |
|
|||||||||||||
| Meningococcal A, C, W, Y (MenACWY) |
1 or 2 doses depending on indication (See Notes for booster recommendations) | |||||||||||||
| Meningococcal B (MenB) |
2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations) | |||||||||||||
| 19 through 23 years | ||||||||||||||
| Haemophilus influenzae type b (Hib) |
1 or 3 doses depending on indication | |||||||||||||
| Mpox |
2 doses | |||||||||||||
| Inactivated poliovirus (IPV) |
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes) | |||||||||||||
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
Additional Information
Report
- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967)
Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Helpful information
- Complete Advisory Committee on Immunization Practices (ACIP) recommendations
- ACIP Shared Clinical Decision-Making Recommendations
- General Best Practice Guidelines for Immunization (including contraindications and precautions)
- Vaccine information statements
- Manual for the Surveillance of Vaccine-Preventable Diseases
(including case identification and outbreak response)